Page 2 - Cell Genomics Changes News Today

Dublin, Jan. 28, 2022 (GLOBE NEWSWIRE) -- The "Genomic Cancer Panel and Profiling Markets by Cancer, by Application, by Tissue and by Gene Type with...

/PRNewswire/ -- The "Genomic Cancer Panel and Profiling Markets by Cancer and Germline/Somatic Type with Screening Potential Market Size, Customized...

/PRNewswire/ -- The "Genomic Cancer Panel and Profiling Markets by Cancer and Germline/Somatic Type with Screening Potential Market Size, Customized...

/PRNewswire/ -- The "Companion Diagnostic Markets 2021-2025" report has been added to ResearchAndMarkets.coms offering. This report provides data that...

Dublin, Oct. 06, 2021 (GLOBE NEWSWIRE) -- The "Respiratory Infection Diagnostic Markets by Technology, Plex, Place, Product and by Region With Covid-19...

/PRNewswire/ -- The "Respiratory Infection Diagnostic Markets by Technology, Plex, Place, Product and by Region With Covid-19 Impact & Forecasting/Analysis,...

/PRNewswire/ -- The "Respiratory Infection Diagnostic Markets by Technology, Plex, Place, Product and by Region With Covid-19 Impact & Forecasting/Analysis,...

3.3.2 Bioinformatics Plays a Role 3.4 Diagnostic Technology Development 3.4.2 Single Cell Genomics Changes the Picture 3.4.3 Pharmacogenomics Blurs Diagnosis and Treatment 3.4.4 CGES Testing, A Brave New World 3.4.5 Biochips/Giant magnetoresistance based assay 4. Cancer Panels & Profiles Recent Developments 4.1 Recent Developments - Importance and How to Use This Section 4.1.1 Importance of These Developments 4.1.2 How to Use This Section Biocartis Collaborating With GeneproDx, Endpoint H...

Will Personalized Companion Diagnostics become the norm for diagnostics? Companion Diagnostics are poised to revolutionize the diagnostics industry. The market is finally moving out of the lab and into the clinic. Oncology, especially immune-oncology is leading the way. And the FDA is holding the door open for this diagnostic technology of the future. But COVID-19 is impacting healthcare treatment everywhere and lowering demand for specialized cancer testing. Find out the latest outlook for thi...

Share this article Share this article ResearchAndMarkets.coms offering. The Multiplex factor is creating market confusion while lowering costs and improving care but important factors are holding back progress. COVID-19 has broken open the market for point of care testing of respiratory infections. Now the competition for market share begins in earnest. Large new markets are opening up. In health facilities, clinics, physicians offices and elsewhere. And lets not forget the screening market, ...